You are here

Home » CERID Bibliography

CERID Bibliography

Export 22 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Humans and Author is Verlinde, Christophe L M J  [Clear All Filters]
2012
Zhang Z, Ojo KK, Johnson SM, Larson ET, He P, Geiger JA, Castellanos-Gonzalez A, White CA, Parsons M, Merritt EA, et al. Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett. 2012 ;22(16):5264-7.
Larson ET, Ojo KK, Murphy RC, Johnson SM, Zhang Z, Kim JE, Leibly DJ, Fox AMW, Reid MC, Dale EJ, et al. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem. 2012 ;55(6):2803-10.
Buckner FS, Bahia MTerezinha, Suryadevara PK, White KL, Shackleford DM, Chennamaneni NKumar, Hulverson MA, Laydbak JU, Chatelain E, Scandale I, et al. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012 ;56(9):4914-21.
Ojo KK, Pfander C, Mueller NR, Burstroem C, Larson ET, Bryan CM, Fox AMW, Reid MC, Johnson SM, Murphy RC, et al. Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J Clin Invest. 2012 ;122(6):2301-5.
Shibata S, Gillespie RJ, Ranade RM, Koh CY, Kim JE, Laydbak JU, Zucker FH, Hol WGJ, Verlinde CLMJ, Buckner FS, et al. Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J Med Chem. 2012 ;55(14):6342-51.
2011
Merritt EA, Arakaki TL, Gillespie R, Napuli AJ, Kim JE, Buckner FS, Van Voorhis WC, Verlinde CLMJ, Fan E, Zucker F, et al. Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. Mol Biochem Parasitol. 2011 ;177(1):20-8.
Ojo KK, Arakaki TL, Napuli AJ, Inampudi KK, Keyloun KR, Zhang L, Hol WGJ, Verlinde CLMJ, Merritt EA, Van Voorhis WC. Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Mol Biochem Parasitol. 2011 ;176(2):98-108.
Larson ET, Kim JE, Zucker FH, Kelley A, Mueller N, Napuli AJ, Verlinde CLMJ, Fan E, Buckner FS, Van Voorhis WC, et al. Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochimie. 2011 ;93(3):570-82.
2010
Kraus JM, Tatipaka HBabu, McGuffin SA, Chennamaneni NKumar, Karimi M, Arif J, Verlinde CLMJ, Buckner FS, Gelb MH. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem. 2010 ;53(10):3887-98.
Arakaki TL, Carter M, Napuli AJ, Verlinde CLMJ, Fan E, Zucker F, Buckner FS, Van Voorhis WC, Hol WGJ, Merritt EA. The structure of tryptophanyl-tRNA synthetase from Giardia lamblia reveals divergence from eukaryotic homologs. J Struct Biol. 2010 ;171(2):238-43.
Ojo KK, Larson ET, Keyloun KR, Castaneda LJ, DeRocher AE, Inampudi KK, Kim JE, Arakaki TL, Murphy RC, Zhang L, et al. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol. 2010 ;17(5):602-7.
2009
Verlinde CLMJ, Fan E, Shibata S, Zhang Z, Sun Z, Deng W, Ross J, Kim J, Xiao L, Arakaki TL, et al. Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium. Curr Top Med Chem. 2009 ;9(18):1678-87.
Kraus JM, Verlinde CLMJ, Karimi M, Lepesheva GI, Gelb MH, Buckner FS. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem. 2009 ;52(6):1639-47.
2008
Bulbule VJ, Rivas K, Verlinde CLMJ, Van Voorhis WC, Gelb MH. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem. 2008 ;51(3):384-7.
Arakaki TL, Buckner FS, Gillespie RJ, Malmquist NA, Phillips MA, Kalyuzhniy O, Luft JR, Detitta GT, Verlinde CLMJ, Van Voorhis WC, et al. Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol. 2008 ;68(1):37-50.
Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan EAW, Chen F, et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov. 2008 ;7(11):900-7.
Ojo KK, Gillespie RJ, Riechers AJ, Napuli AJ, Verlinde CLMJ, Buckner FS, Gelb MH, Domostoj MM, Wells SJ, Scheer A, et al. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother. 2008 ;52(10):3710-7.
Larson ET, Deng W, Krumm BE, Napuli A, Mueller N, Van Voorhis WC, Buckner FS, Fan E, Lauricella A, Detitta G, et al. Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. J Mol Biol. 2008 ;381(4):975-88.
2007
Van Voorhis WC, Rivas KL, Bendale P, Nallan L, Hornéy C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, et al. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother. 2007 ;51(10):3659-71.
2006
Robien MA, Bosch J, Buckner FS, Van Voorhis WCE, Worthey EA, Myler P, Mehlin C, Boni EE, Kalyuzhniy O, Anderson L, et al. Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 A resolution reveals intriguing extra electron density in the active site. Proteins. 2006 ;62(3):570-7.
2005
Hucke O, Gelb MH, Verlinde CLMJ, Buckner FS. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005 ;48(17):5415-8.
Eastman RT, White J, Hucke O, Bauer K, Yokoyama K, Nallan L, Chakrabarti D, Verlinde CLMJ, Gelb MH, Rathod PK, et al. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem. 2005 ;280(14):13554-9.